GPR30 gene polymorphisms are associated with gynecomastia risk in adolescents

Hormone Research in Paediatrics

Volumn 83, Issue 3, 2015, Pages 177-182

  Korkmaz, Hüseyin Anil ^a   Edgünlü, Tuba ^b   Eren, Erdal ^c   Demir, Korcan ^d   Çakir, Esra Deniz Papatya ^e   Çelik, Sevim Karaka ^f   Özkan, Behzat ^a  

^a Dr Behcet Uz Child Disease and Surgery Training and Research Hospital   (Turkey)

^b MUGLA SITKI KOCMAN UNIVERSITY   (Turkey)

^c HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^d Gaziantep Children's Hospital   (Turkey)

^e Mersin Women's and Children's Hospital   (Turkey)

^f ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Estrogen; GPR30; Gynecomastia; Polymorphism

Indexed keywords

DNA; ESTRADIOL; FOLLITROPIN; G PROTEIN COUPLED RECEPTOR 30; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROLACTIN; TESTOSTERONE; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; HORMONE;

ADOLESCENT; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ESTRADIOL BLOOD LEVEL; FOLLITROPIN BLOOD LEVEL; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; GYNECOMASTIA; HAPLOTYPE; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TESTOSTERONE BLOOD LEVEL; ADULT; ALLELE; BLOOD; CLINICAL TRIAL; GENETICS; METABOLISM;

ADOLESCENT; ADULT; ALLELES; GENE FREQUENCY; GYNECOMASTIA; HORMONES; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84928625021     PISSN: 16632818     EISSN: 16632826     Source Type: Journal    
DOI: 10.1159/000369013     Document Type: Article

References (22)

1. Carlson HE: Approach to the patient with gynecomastia. J Clin Endocrinol Metab 2011; 96: 15-21
2. Gikas P, Mokbel K: Management of gynaecomastia: an update. Int J Clin Pract 2007; 61: 1209-1215
3. Rahmani S, Turton P, Shaaban A, Dall B: Overview of gynecomastia in the modern era and the Leeds Gynaecomastia Investigation algorithm. Breast J 2011; 17: 246-255
4. Bembo SA, Carlson HE: Gynecomastia: its features, and when and how to treat it. Cleve Clin J Med 2004; 71: 511-517
5. Andersen J, Orntoft TF, Andersen JA, Poulsen HS: Gynecomastia. Immunohistochemical demonstration of estrogen receptors. Acta Pathol Microbiol Immunol Scand A 1987; 95: 263-267
6. Poulsen HS, Hermansen C, Andersen JA, Andersen HU, Jensen J: Gynecomasty: estrogen and androgen receptors. A clinical-pathological investigation. Acta Pathol Microbiol Immunol Scand A 1985; 93: 229-233
7. Czajka-Oraniec I, Zgliczynski W, Puzianowska-Kuznicka M, Kurylowicz A, Mikula M, Ostrowski J: Role of c.454-351A/G polymorphism of estrogen receptor alpha gene in genetic predisposition to idiopathic gynecomastia. 5th Conf Sect Mol Endocrinol, Polish Soc Endocrinol, Poznan, March 2007
8. Eren E, Edgunlu T, Korkmaz HA, Cakir ED, Demir K, Cetin ES, Celik SK: Genetic variants of estrogen beta and leptin receptors may cause gynecomastia in adolescent. Gene 2014; 541: 101-106
9. Giess M, Lattrich C, Springwald A, Goerse R, Ortmann O, Treeck O: GPR30 gene polymorphisms are associated with progesterone receptor status and histopathological characteristics of breast cancer patients. J Steroid Biochem Mol Biol 2010; 118: 7-12
10. Filardo EJ, Quinn JA, Bland KI, Frackelton AR Jr: Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 2000; 14: 1649-1660
11. Bologa CG, Revankar CM, Young SM, Edwards BS, Arterburn JB, Kiselyov AS, Parker MA, Tkachenko SE, Savchuck NP, Sklar LA, Oprea TI, Prossnitz ER: Virtual and biomolecular screening converge on a selective agonist for GPR30. Nat Chem Biol 2006; 2: 207-212
12. Albanito L, Madeo A, Lappano R, Vivacqua A, Rago V, Carpino A, Oprea TI, Prossnitz ER, Musti AM, Ando S, Maggiolini M: G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 2007; 67: 1859-1866
13. Pandey DP, Lappano R, Albanito L, Madeo A, Maggiolini M, Picard D: Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 2009; 28: 523-532
14. Kleuser B, Malek D, Gust R, Pertz HH, Potteck H: 17-estradiol inhibits transforming growth factor signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30. Mol Pharmacol 2008; 74: 1533-1543
15. Chevalier N, Paul-Bellon R, Camparo P, Michiels JF, Chevallier D, Fenichel P: Genetic variants of GPER/GPR30, a novel estrogenrelated G protein receptor, are associated with human seminoma. Int J Mol Sci 2014; 15: 1574-1589
16. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, Wei R, Curtin LR, Roche AF, Johnson CL: 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002; 246: 1-190
17. Filardo EJ, Quinn JA, Sabo E: Association of the membrane estrogen receptor, GPR30, with breast tumor metastasis and transactivation of the epidermal growth factor receptor. Steroids 2008; 73: 870-873
18. Albanito L, Sisci D, Aquila S, Brunelli E, Vivacqua A, Madeo A, Lappano R, Pandey DP, Picard D, Mauro L, Ando S, Maggiolini M: Epidermal growth factor induces G proteincoupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 2008; 149: 3799-3808
19. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E: Distribution of GPR30, a seven membranespanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 2006; 12: 6359-6366
20. Huang GS, Gunter MJ, Arend RC, Li M, Arias-Pulido H, Prossnitz ER, Goldberg GL, Smith HO: Co-expression of GPR30 and ER and their association with disease progression in uterine carcinosarcoma. Am J Obstet Gynecol 2010; 203: 242
21. Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER: GPR30 predicts poor survival for ovarian cancer. Gynecol Oncol 2009; 114: 465-471
22. Filardo EJ, Thomas P: Minireview: G proteincoupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer, renal and vascular physiology. Endocrinology 2012; 153: 2953-2962.